Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Nov;24(6):233-8.
doi: 10.1016/j.blre.2010.08.003. Epub 2010 Sep 15.

Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma

Adam Jona  1 , Anas Younes
Affiliations
Review

Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma

Adam Jona et al. Blood Rev. 2010 Nov.

Abstract

The treatment of patients with relapsed and refractory Hodgkin lymphoma (HL), especially those who relapse after autologous stem cell transplantation, remains challenging. Patients with HL whose disease relapses after stem cell transplantation are rarely cured with current treatment modalities, and have a median survival of less than 3 years. Since no new drugs have been approved by the FDA for HL in more than three decades, there is a clear unmet medical need for drug development for this patient population. New treatment strategies that are based on targeting oncogenic signaling pathways are currently explored. This review will focus on emerging new treatment modalities that are currently under investigation for patients with relapsed classical HL.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

A. Younes declares the following conflicts of interest:

Research funding and honoraria from Genetech.

Research funding and honoraria from SBIO.

Research funding and honoraria from Novartis.

Research funding and honoraria from Seattle Genetics.

A. Jona has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin. 2009;59:225–249. - PubMed
    1. Horning S, Fanale MSd. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort [abstract] Ann Oncol. 2008;20:118.
    1. Buglio D, Georgakis G, A Y. Novel small-molecule therapy of Hodgkin lymphoma. Expert Rev Anticancer Ther. 2007;7:735–740. - PubMed
    1. Kuppers R. The biology of Hodgkin’s lymphoma. Nat Rev Cancer. 2009;9:15–17. - PubMed
    1. Younes A, Carbone A. CD30/CD30 ligand and CD40/ CD40 ligand in malignant lymphoid disorders. Int J Biol Markers. 1999;14:135–143. - PubMed